|
|
|
| Advances of Biotherapy for Treating Intraocular Malignant Tumor |
| Yuxin Li1, Wei Wei2, Yong Tao1, Xiaojun Wang1 |
| 1Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China2State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China |
|
|
|
| Guide |
|
|
Abstract Intraocular malignant tumors, which are serious blinding diseases and can even be life-threatening, mostly occur in the retina and uvea. With the rapid development of biotechnology, biotherapy for intraocular malignant tumors has evolved to include immunotherapy, small molecule targeted therapy, gene therapy and oncolytic virus therapy. This review summarized the recent advances, current problems, and future perspectives in the fundamental and clinical research of biotherapy for treating retinoblastoma and uveal melanoma, the most common primary intraocular malignancies in children and adults.
|
|
Received: 30 November 2022
|
|
|
| Fund:National Natural Science Foundation of China (82070948); Beijing HospitalsAuthority'sAscent Plan (DFL20220301); Golden Seed Fund Project of Beijing Chaoyang Hospital (CYJZ202139) |
|
Corresponding Authors:
Xiaojun Wang, Email: wxj20061117@126.com
|
|
|
|
| [1] |
. [J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2023, 25(8): 0-. |
|
|
|
|
